Related Experiment Video
Updated: Jul 6, 2025
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
[Treatment of Juvenile Myasthenia Gravis]
1Department of Pediatrics, Tokyo Women's Medical University School of Medicine.
Insights
Juvenile myasthenia gravis (JMG) differs from adult forms, often presenting with ocular symptoms and lower antibody rates. Adequate steroid doses show high remission rates in children, despite concerns about growth retardation.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Context:
- Juvenile myasthenia gravis (JMG) shares pathogenic similarities with adult-onset myasthenia gravis.
- JMG predominantly manifests as ocular type, with distinct characteristics including low antibody-positive rates, low thymoma complication rates, and high remission rates.
Purpose:
- To evaluate the efficacy and safety of treatment strategies for juvenile myasthenia gravis.
- To address the insufficient evidence for adult treatment protocols in pediatric populations.
- To investigate the risks associated with immunosuppressive drugs and steroid use in children.
Summary:
- Current evidence supporting low-dose steroids and fast-acting treatments for adult myasthenia gravis is inadequate for pediatric use.
- Steroid therapy in children necessitates caution due to potential growth retardation; lower doses are desirable but less investigated for efficacy.
- Clinical experience indicates that adequate steroid doses achieve high remission rates in JMG, challenging the rationale for lower-dose recommendations.
Impact:
- Highlights the need for pediatric-specific treatment guidelines for juvenile myasthenia gravis.
- Informs clinical practice regarding the appropriate use of corticosteroids in managing JMG.
- Emphasizes the importance of balancing treatment efficacy with potential adverse effects like growth impairment in pediatric patients.
Abstract:
The pathogenesis of juvenile myasthenia gravis is similar to that of adult-onset cases, but does differ significantly in that it is predominantly ocular type, has a low antibody-positive rate, a low thymoma complication rate, and a high remission rate. The evidence for the adult treatment strategy of low-dose steroids and fast-acting treatment is insufficient in children, and the safety of immunosuppressive drugs has not been established. Steroid use in children in particular requires caution due to the risk of growth retardation, and while lower doses are desirable, the efficacy of lower doses has not been as fully investigated as in adults. Conversely, experience has shown that the use of adequate doses of steroids results in high remission rates, and there is currently no rationale for recommending lower doses.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:26Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...